China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage.
The Chinese trial tested ivonescimab and chemotherapy against AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy on a total of 682 patients with advanced biliary tract cancer – a particularly deadly form of cancer with a five-year survival rate of less than 5 per cent, according to a Nature study.
The results showed that patients taking Akeso’s novel drug lived longer than those using the AstraZeneca treatment, the company said in a Hong Kong stock exchange filing released a day ahead of its interim results.
The study marks the first positive phase-three study for ivonescimab in gastrointestinal tumours, potentially opening the door for the drug to be used in a “broader range of solid tumours”, said Xia Yu, Akeso’s founder, chairwoman and CEO.
However, Akeso has yet to disclose the exact survival figures from the trial, which the Zhongshan-headquartered company is expected to present at an coming conference.

Facts Only

* Akeso announced its immunotherapy drug ivonescimab outperformed AstraZeneca’s Imfinzi in a phase-three trial for biliary tract cancer.
* The trial tested ivonescimab and chemotherapy against AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy.
* The trial involved 682 patients with advanced biliary tract cancer.
* Patients taking Akeso’s novel drug lived longer than those using the AstraZeneca treatment.
* ivonescimab has also shown promise in treating some lung cancers.
* Akeso’s ivonescimab has been licensed by Summit Therapeutics.
* The study marks the first positive phase-three study for ivonescimab in gastrointestinal tumors.
* The company is expected to present exact survival figures at an upcoming conference.

Executive Summary

A Chinese biopharmaceutical firm, Akeso, announced that its immunotherapy drug ivonescimab outperformed AstraZeneca’s Imfinzi in a phase-three trial for advanced biliary tract cancer. The trial compared ivonescimab and chemotherapy against Imfinzi plus chemotherapy across 682 patients with this aggressive cancer. The results indicated that patients receiving Akeso’s novel drug experienced longer survival times than those using the AstraZeneca treatment. This finding represents the first positive phase-three study for ivonescimab in gastrointestinal tumors, potentially expanding its use to a broader range of solid tumors. While the company reported favorable outcomes, specific survival figures from the trial remain undisclosed and are expected at a future conference.

Full Take

The narrative centers on the emerging competitive landscape of the global biopharma industry, where novel immunotherapy agents are being tested against established standards of care for aggressive cancers. The significance lies not just in the observed differential outcome but in the potential paradigm shift suggested by the finding: establishing a new benchmark for efficacy in a notoriously fatal disease like biliary tract cancer. Akeso’s success in this specific trial signals that targets beyond traditional chemotherapy combinations may yield meaningful clinical advantages, pushing research toward broader applications in solid tumors. The withholding of exact survival metrics until a formal presentation introduces a strategic element; it allows the initial announcement to generate excitement while maintaining control over highly sensitive data until framed by official figures. This creates an immediate tension between the kinetic promise of the preliminary result and the measured reality required for clinical acceptance. The pattern observed is one where competitive advantage in a high-stakes therapeutic area is leveraged through phased disclosure, which can manage market perception versus scientific rigor. What factors will influence future adoption beyond this single trial—cost-effectiveness, dosing regimens across different patient populations, and real-world durability of the response—remain open questions that will define the trajectory of this breakthrough.

Sentinel — Human

Confidence

The text reads like standard, fact-based financial/biotech reporting, characterized by clear attribution and specific references to regulatory events rather than abstract synthesis.

Signals Detected

Sentence length variance is natural; the flow is journalistic but not overly uniform.

The text flows logically, presenting facts and context without excessive hedging or an unnatural voice.

Attribution is clear (Akeso announced; Xia Yu said) and references specific regulatory/scientific bodies (Nature study, HK exchange filing).

The core claims are tied to verifiable public filings and scientific reporting structures.

Human Indicators

Inclusion of specific, verifiable details like the exact trial comparison (ivonescimab vs. Imfinzi), patient count (682 patients), and direct corporate filings provides strong grounding.